New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
Go back to New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 2.97 +0.04 (1.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.93 | 52 Week High | $54.24 | |||
| Open | $2.88 | 52 Week Low | $48.35 | |||
| Day High | $3.04 | P/E | N/A | |||
| Day Low | $2.88 | EPS | $0.00 | |||
| Volume | 1,153,537 | |||||
